↓ Skip to main content

Isoniazid for preventing tuberculosis in HIV-infected children

Overview of attention for article published in Cochrane database of systematic reviews, August 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (90th percentile)
  • Good Attention Score compared to outputs of the same age and source (68th percentile)

Mentioned by

blogs
2 blogs
policy
1 policy source
twitter
11 tweeters
facebook
1 Facebook page
wikipedia
1 Wikipedia page

Citations

dimensions_citation
24 Dimensions

Readers on

mendeley
163 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Isoniazid for preventing tuberculosis in HIV-infected children
Published in
Cochrane database of systematic reviews, August 2017
DOI 10.1002/14651858.cd006418.pub3
Pubmed ID
Authors

Moleen Zunza, Diane M Gray, Taryn Young, Mark Cotton, Heather J Zar

Abstract

Tuberculosis (TB) is an important cause of illness and death in HIV-positive children living in areas of high TB prevalence. We know that isoniazid prophylaxis prevents TB in HIV-negative children following TB exposure, but there is uncertainty related to its role in TB preventive treatment in HIV-positive children. To summarise the effects of TB preventive treatment versus placebo in HIV-positive children with no known TB contact on active TB, death, and reported adverse events. We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE/PubMed, Embase and two trial registers up to February 2017. We included trials of HIV-positive children with and without known TB exposure, randomized to receive TB preventive treatment or placebo. Two review authors independently used the study selection criteria, assessed risk of bias, and extracted data. We assessed effects using risk, incidence rate and hazard ratios and assessed the certainty of evidence using GRADE. We included three trials, involving 991 participants, below the age of 13 years, from South Africa and Botswana. Children were randomized to isoniazid prophylaxis or placebo, given daily or three times weekly. The median length of follow-up ranged from 5.7 to 34 months; some were on antiretroviral therapy (ART).In HIV-positive children not on ART, isoniazid prophylaxis may reduce the risk of active TB (hazard ratio (HR) 0.31, 95% confidence interval (CI) 0.11 to 0.87; 1 trial, 240 participants, low certainty evidence), and death (HR 0.46, 95% CI 0.22 to 0.95; 1 trial, 240 participants, low certainty evidence). One trial (182 participants) reported number of children with laboratory adverse events, which was similar between the isoniazid prophylaxis and placebo groups. No clinical adverse events were reported.In HIV-positive children on ART, we do not know if isoniazid prophylaxis reduces the risk of active TB (risk ratio (RR) 0.76, 95% CI 0.50 to 1.14; 3 trials, 737 participants, very low certainty evidence) or death (RR 1.45, 95% CI 0.78 to 2.72; 3 trials, 737 participants, very low certainty evidence). Two trials (714 participants) reported number of clinical adverse events and three trials (795 participants) reported number of laboratory adverse events; for both categories, the number of adverse events were similar between the isoniazid prophylaxis and placebo groups. Isoniazid prophylaxis given to all children diagnosed with HIV may reduce the risk of active TB and death in HIV-positive children not on ART in studies from Africa. For children on ART, no clear benefit was detected. .

Twitter Demographics

The data shown below were collected from the profiles of 11 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 163 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 163 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 35 21%
Researcher 24 15%
Student > Bachelor 20 12%
Student > Ph. D. Student 13 8%
Student > Postgraduate 11 7%
Other 32 20%
Unknown 28 17%
Readers by discipline Count As %
Medicine and Dentistry 64 39%
Nursing and Health Professions 24 15%
Social Sciences 7 4%
Pharmacology, Toxicology and Pharmaceutical Science 5 3%
Immunology and Microbiology 4 2%
Other 24 15%
Unknown 35 21%

Attention Score in Context

This research output has an Altmetric Attention Score of 24. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 August 2020.
All research outputs
#888,358
of 15,882,608 outputs
Outputs from Cochrane database of systematic reviews
#2,456
of 11,314 outputs
Outputs of similar age
#25,498
of 273,028 outputs
Outputs of similar age from Cochrane database of systematic reviews
#80
of 254 outputs
Altmetric has tracked 15,882,608 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,314 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 23.6. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 273,028 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 254 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.